Miami billionaire Ken Griffin is accustomed to making headlines for what he is building, buying or reshaping in South Florida.<\/p>\n
The Citadel founder has become one of the most influential figures in Miami\u2019s transformation into a major financial and business center with his real estate purchases from Coconut Grove to West Palm Beach.<\/p>\n
But over the past week, it\u2019s been revealed in finance circles that Griffin, who manages one of the world\u2019s largest hedge funds, has been making news for practicing his profession: buying and selling stocks.<\/p>\n
His latest portfolio moves involve two pharmaceutical companies and a troubled artificial intelligence company are giving investors a glimpse into how one of the world\u2019s most closely watched hedge fund managers is navigating an expensive and increasingly volatile market.<\/p>\n
In the Situational Awareness fund move, Griffin sent investors a letter explaining Citadel\u2019s stock actions with the AI company.<\/p>\n
In the case of the two pharma companies, they were made public in the hedge fund\u2019s Form 13F, a quarterly report filed with the U.S. Securities and Exchange Commission by institutional investment managers with at least $100 million in qualifying assets.<\/p>\n
Here\u2019s what to know:<\/p>\n
![\"Billionaire](\"https:\/\/www.newsbeep.com\/us-fl\/wp-content\/uploads\/2026\/08\/1787921289_226_MIA_04GRITTINVISITBOOKERT.JPG\" "\\"MIA_04GRITTINVISITBOOKERT.JPG\\"")
Billionaire Ken Griffin speaks to students during an assembly at Booker T. Washington Senior High School on Tuesday, Feb. 24, 2026, in Miami, Florida. Carl Juste cjuste@miamiherald.com Griffin goes big on Eli Lilly<\/p>\n
In the latest move this week, financial reports show, Citadel nearly quadrupled its position in Eli Lilly during the second quarter, adding roughly 700,000 shares and bringing its holdings to about 945,000 shares, worth roughly $1.2 billion at the time of the filing.<\/p>\n
The move puts Lilly among Citadel\u2019s largest individual stock positions and comes after the pharma giant\u2019s shares suffered a sharp decline earlier this year before rebounding.<\/p>\n
Lilly\u2019s weight-loss drugs Mounjaro and Zepbound have made it a dominant player in the booming diabetes and obesity-treatment markets. The company reported roughly $23 billion in second-quarter revenue, up 48% from a year earlier, with Mounjaro generating about $9.9 billion and Zepbound approximately $4.9 billion.<\/p>\n
The investment also gives Griffin exposure to Lilly\u2019s Alzheimer\u2019s drugs. The company\u2019s Kisunla treatment received FDA approval in 2024 for certain patients with early symptomatic Alzheimer\u2019s disease.<\/p>\n
There is a notable Miami connection to Griffin\u2019s philanthropy. In 2024, Griffin donated $50 million to Baptist Health Miami Neuroscience Institute,<\/a> helping establish the Kenneth C. Griffin Center for neurological care and research at the Kendall hospital.<\/p>\n Griffin ads AbbVie as second pharma bet<\/p>\n Lilly wasn\u2019t Griffin\u2019s only major pharmaceutical move. Citadel increased its AbbVie position by roughly 547% during the second quarter, adding about 2.7 million shares and ending the period with approximately 3.2 million shares worth around $800 million.<\/p>\n AbbVie offers a different investment profile from Lilly, with established drugs including Skyrizi, Rinvoq and Botox and a dividend that has increased for more than five decades.<\/p>\n The two investments together suggest Citadel is looking beyond a single pharmaceutical trade, pairing Lilly\u2019s high-growth story with AbbVie\u2019s established products and cash generation, experts say.<\/p>\n Griffin gives \u2018master class\u2019<\/p>\n The phrase \u201cmasterclass\u201d is actually tied to Griffin\u2019s handling of an entirely different trade: the collapse of AI-focused hedge fund Situational Awareness.<\/p>\n The fund, founded by former OpenAI researcher Leopold Aschenbrenner, suffered a 67% decline in July as heavily concentrated AI-related positions plunged.<\/p>\n Then Citadel stepped in to purchase much of the distressed portfolio at a discount.<\/p>\n Citadel subsequently sold more than 80% of the acquired exposure through nearly 100 block trades worth more than $4 billion in market value, according to reports.<\/p>\n